CalciMedica Pauses Auxora Trial Enrollment, Awaits FDA Feedback on Pivotal Program in Q3
Summary
CalciMedica has paused enrollment in its Auxora trial since January 2026 and amended it in March, now awaiting FDA feedback on a potential pivotal program in Q3. This follows positive Phase 2b results for Auxora reported in May. While the company recently secured $15 million in new financing, the pause in a lead candidate's trial introduces significant uncertainty for this micro-cap biotech. Traders should watch for the FDA feedback expected in Q3 2026.
At the time of this announcement, CALC was trading at $0.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.4M. The 52-week trading range was $0.46 to $7.20. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.